JNCE - Jounce Therapeutics GAAP EPS of -$0.59 misses by $0.27

Jounce Therapeutics press release (NASDAQ:JNCE): Q4 GAAP EPS of -$0.59 misses by $0.27. As of December 31, 2021, cash, cash equivalents and investments were $220.2 million, compared to $213.2 million as of December 31, 2020. FY22 Guidance: Gross cash burn on operating expenses and capital expenditures for the full year 2022 is expected to be approximately $115.0 million to $130.0 million. Existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the third quarter of 2023.

For further details see:

Jounce Therapeutics GAAP EPS of -$0.59 misses by $0.27